Logo do repositório
 
Miniatura
Publicação

MCT1 is a new prognostic biomarker and its therapeutic inhibition boosts response to Temozolomide in human glioblastoma

2021-07-11Artigo de investigação Acesso aberto
http://hdl.handle.net/10400.22/31539
Utilize este identificador para referenciar este registo.
Nome:Descrição:Tamanho:Formato: 
ART_Sara Granja2.pdf1.92 MBAdobe PDF Ver/Abrir

Autores

Gonçalves, Vera Miranda
Gonçalves, Céline S.
Granja, Sara
Castro, Joana Vieira de
Reis, Rui M.
Costa, Bruno M.
Baltazar, Fátima

Orientador(es)

Resumo(s)

Glioblastoma, the brain tumour with highest prevalence and lethality, exhibits a characteristic glycolytic phenotype with increased lactate production. Recently, we reported a MCT1 overexpression in GBMs tumours, being associated to tumour growth and aggressiveness. Thus, we aimed to disclose the role of MCT1 in GBM prognosis and in vivo therapy response. Importantly, MCT1 overexpression is associated with poor prognosis of GBM. Moreover, MCT1 inhibition retards GBM tumour growth and boosts response to temozolomide treatment.

Descrição

Palavras-chave

Monocarboxylate transporters Glioblastoma Lactate Warburg effect Prognostic biomarker

URI

http://hdl.handle.net/10400.22/31539

Contexto Educativo

Citação

Miranda-Gonçalves, V., Gonçalves, C. S., Granja, S., Vieira de Castro, J., Reis, R. M., Costa, B. M., & Baltazar, F. (2021). MCT1 Is a New Prognostic Biomarker and Its Therapeutic Inhibition Boosts Response to Temozolomide in Human Glioblastoma. Cancers, 13(14), 3468. https://doi.org/10.3390/cancers13143468

Projetos de investigação

Unidades organizacionais

Fascículo

Editora

MDPI

DOI

10.3390/cancers13143468

Coleções

ESS - CISA - Artigos
ESS - APCT - Artigos

Licença CC

cclicense-by

Métricas Alternativas